[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500905":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":146,"collaborators":32,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":156,"sex":157,"minAge":158,"maxAge":32,"enrollmentInfo":159,"targetDuration":32,"studyType":162,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":182},{"fullName":5,"class":6},"Ocugen","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","3+3 participants will receive intravitreal injection of OCU200 (0.5 mg\u002FmL concentration).",[13],"Drug: OCU200",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","3+3 participants will receive intravitreal injection of OCU200 (1 mg\u002FML concentration).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","3+3 participants will receive intravitreal injection of OCU200 (2 mg\u002FmL concentration).",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","3+3 participants will receive intravitreal injection of OCU200 (5 mg\u002FmL concentration).",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","OCU200","Intravitreal Injection",[9,15,19,23],null,[34],{"name":35,"affiliation":5,"role":36},"Huma Qamar, MD, MPH, CMI","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Roshan A George, MD, MPH","CONTACT","845-664-1505","roshan.george@ocugen.com",{"name":44,"role":40,"phone":32,"phoneExt":32,"email":45},"Oscar Cuzzani, MD, PhD","Oscar.Cuzzani@ocugen.com",[47,73,90,107,126],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Advanced Research LLC","RECRUITING","Deerfield Beach","Florida","33064","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-80.09977,26.31841,{"lat":59,"lon":58},[62,67,70],{"name":63,"role":40,"phone":64,"phoneExt":65,"email":66},"Danahe Navarrete","954-302-3047","103","dnavarrete@advancedresearchfl.com",{"name":68,"role":40,"phone":32,"phoneExt":32,"email":69},"Samarth Shah, MD, Ph.D","sshah@advancedresearchfl.com",{"name":71,"role":72,"phone":32,"phoneExt":32,"email":32},"Shailesh Gupta, MD","PRINCIPAL_INVESTIGATOR",{"facility":74,"status":49,"city":75,"state":76,"zip":77,"country":53,"countryCode":54,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Erie Retina Research, LLC","Erie","Pennsylvania","16507",{"type":56,"coordinates":79},[80,81],-80.08506,42.12922,{"lat":81,"lon":80},[84,88],{"name":85,"role":40,"phone":86,"phoneExt":32,"email":87},"Bethany Scott","814-737-0203","b.scott.research@pm.me",{"name":89,"role":72,"phone":32,"phoneExt":32,"email":32},"David Almeida, MD, MDA, PhD",{"facility":91,"status":49,"city":92,"state":93,"zip":94,"country":53,"countryCode":54,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Retina Consultants of Texas Research Centers","Bellaire","Texas","77401",{"type":56,"coordinates":96},[97,98],-95.45883,29.70579,{"lat":98,"lon":97},[101,105],{"name":102,"role":40,"phone":103,"phoneExt":32,"email":104},"Rebecca Taing","713-394-7576","rebbecca.taing@retinaconsultantstexas.com",{"name":106,"role":72,"phone":32,"phoneExt":32,"email":32},"Charles Wykoff, MD",{"facility":108,"status":49,"city":109,"state":93,"zip":110,"country":53,"countryCode":54,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Retina Consultants of America","Southlake","76092",{"type":56,"coordinates":112},[113,114],-97.13418,32.94124,{"lat":114,"lon":113},[117,121,124],{"name":118,"role":40,"phone":119,"phoneExt":32,"email":120},"Lydia Adams","800-833-5921","lydia.adams@retinaconsultantstexas.com",{"name":122,"role":40,"phone":32,"phoneExt":32,"email":123},"Emily Gonzales","emily.gonzales@retinaconsultantstexas.com",{"name":125,"role":72,"phone":32,"phoneExt":32,"email":32},"R.Gary Lane, MD",{"facility":127,"status":49,"city":128,"state":129,"zip":130,"country":53,"countryCode":54,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Gundersen Health System","La Crosse","Wisconsin","54601",{"type":56,"coordinates":132},[133,134],-91.23958,43.80136,{"lat":134,"lon":133},[137,141,144],{"name":138,"role":40,"phone":139,"phoneExt":32,"email":140},"Trinity Lee","608-775-9539","trinity.lee@emplifyhealth.org",{"name":142,"role":40,"phone":32,"phoneExt":32,"email":143},"Chase Penzkover","chase.penzkover@emplifyhealth.org",{"name":145,"role":72,"phone":32,"phoneExt":32,"email":32},"Syed M Shah, MD",{"type":147,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100500905","phase-1-phase-i-study-to-assess-the-safety-and-efficacy-of-ocu200-for-center-involved-diabetic-macular-edema-dme-100500905",false,"NCT05802329","Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)","A Phase 1 Study To Assess The Safety And Efficacy Of OCU200 For Center-Involved Diabetic Macular Edema","DME","Inclusion Criteria:\n\n1. Diagnosis of Type 1 or Type 2 Diabetes Mellitus\n2. Decreased visual acuity attributable primarily to DME\n3. Central-involved DME with central retinal subfield thickness (CST) values, as assessed with spectral-domain optical coherence tomography (SD-OCT) of:\n\n   1. ≥ 320 but ≤ 450µm if male or ≥ 305 but ≤ 435µm if female on Heidelberg Spectralis\n   2. ≥ 305 but ≤ 435µm if male or ≥ 290 but ≤ 420µm if female on Zeiss Cirrus\n4. BCVA ≤ 78 and ≥ 24 letters on ETDRS chart\n5. Sufficient ocular media clarity, pupillary dilation and participant cooperation to permit acquisition of good quality retinal imaging\n6. No history of prior anti-VEGF injection or history of at least 2 consecutive intravitreal anti-VEGF injection (less than 7 weeks apart) with incomplete resolution of CST within 1 year.\n\nNote: The last anti-VEGF injection must be administered at least six weeks (45 days) prior to the study treatment (Day 1) in the study eye.\n\nExclusion Criteria:\n\n1. Presence of any condition that prevent clear visualization of retina (e.g., significant cataract, vitreous hemorrhage)\n2. Uncontrolled hypertension\n3. Uncontrolled glaucoma\n4. Concurrent disease in the study eye, other than central-involved DME\n5. Intravitreal or periocular steroid treatment within 3 months prior to the screening visit\n6. Any ocular surgery within 3 months prior to the screening visit in the study eye\n7. Uncontrolled\u002Fpoorly controlled diabetes (Glycated hemoglobin (HbA1c) ≥ 10%)\n8. History of retinal detachment in the study eye or other retinal vascular disease in the study eye\n9. Focal or pan-retinal laser photocoagulation in the study eye within 3 months prior to the screening visit\n10. Presence of any inherited retinal disease or history of proliferative diabetic retinopathy\n11. History of Renal disease including stage 3b or worse",true,"ALL","18 Years",{"count":160,"type":161},24,"ESTIMATED","INTERVENTIONAL",[164],"PHASE1","A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema",[167,168],"Center Involved Diabetic Macular Edema","Diabetic Macular Edema",[170,171,172,154],"anti-VEGF","Transferrin","Tumstatin","2025-11-25",{"date":175,"type":176},"2025-12-03","ACTUAL",{"date":178,"type":176},"2024-01-13",{"date":180,"type":161},"2026-07-31",{"name":5,"class":6},5]